Experience

Mabwell Bioscience Announces Formation of Kalexo Bio With Aditum Bio

September 17, 2025

Cooley advised Mabwell Bioscience, an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain, on its exclusive license agreement with Aditum Bio to launch Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target small interfering RNA (siRNA) candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease events.

Read more

Related contacts

Charity Williams
Partner, San Diego
Freddy Yip
Associate, Hong Kong
Ken Rollins
Partner in Charge – San Diego, San Diego
Brett Dovman
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Hengrui Pharma and Braveheart Bio Enter Into Exclusive License Agreement

September 5, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Steve Przesmicki
Partner, San Diego
Navya Dasari
Associate, New York
Max Levinbook
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

July 27, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Frances Stocks Allen
Partner, London
Jiqiang Lin
Associate, New York
Freddy Yip
Associate, Hong Kong
Aaron Pomeroy
Partner, Colorado
David Wilson
Partner, London
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Robert Eisenbach
Of Counsel, San Francisco
Navya Dasari
Associate, New York
Rick Jantz
Associate, Santa Monica
Eerik Kukebal
Associate, London
Daniel Millard
Associate, London
Patrick Sharma
Associate, Santa Monica
Zhijing Yu
Associate, Singapore

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca

March 17, 2025

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Rowook Park
Partner, San Diego
Charity Williams
Partner, San Diego
Simon Amies
Partner, London
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Christopher Kimball
Partner, Washington, DC
Charlie Lightfoot
Partner, London
Alessandra Murata
Partner, Palo Alto
Guadalupe Sampedro
Partner, London
Stella Sarma
Partner, Brussels
Leo Spicer-Phelps
Partner, London
Nicola Squire
Partner, London
Chris Stack
Partner, London
Jeffrey J. Tolin
Partner, New York
David Wilson
Partner, London
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Jack Jones
Special Counsel, London
Dillon Martinson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Julie Wicklund
Special Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Kafeel Azher
Associate, London
Sarah Buchik
Associate, New York
Mari Dugas
Associate, Washington, DC
Michael Fernando
Associate, London
Athina Gaki
Associate, Brussels
Elaine Huang
Associate, Palo Alto
Mark Jones
Associate, London
Eerik Kukebal
Associate, London
Chris Lynn
Associate, London
Morgan McCormack
Associate, London
Daniel Millard
Associate, London
Lindsey O'Crump
Associate, Washington, DC
Alexandra Paterson
Associate, London
Zhijing Yu
Associate, Singapore
Kevin Gurley
Quantitative Analyst, New York

Related Practices & Industries

View more

Admissions and credentials

New York

Certified Information Privacy Professional/Asia (CIPP/ASIA)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.